Autolus Therapeutics plc (NASDAQ:AUTL) Shares Purchased by Bellevue Group AG

Bellevue Group AG boosted its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 27.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,500 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. Bellevue Group AG’s holdings in Autolus Therapeutics were worth $151,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 2nd quarter valued at approximately $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the 3rd quarter valued at about $51,000. Daiwa Securities Group Inc. lifted its stake in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new position in Autolus Therapeutics during the third quarter worth $91,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of Autolus Therapeutics during the 1st quarter valued at about $108,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Friday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Trading Up 1.5 %

NASDAQ:AUTL opened at $3.32 on Monday. Autolus Therapeutics plc has a 12-month low of $2.69 and a 12-month high of $7.45. The stock’s 50 day simple moving average is $3.72 and its 200-day simple moving average is $3.91. The firm has a market cap of $883.42 million, a P/E ratio of -2.74 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the business earned ($0.26) EPS. Research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.